Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.1099/jmm.0.001203

http://scihub22266oqcxt.onion/10.1099/jmm.0.001203
suck pdf from google scholar
32469301!7451031!32469301
unlimited free pdf from europmc32469301    free
PDF from PMC    free
html from PMC    free

suck abstract from ncbi


Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534

Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534

Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534

Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534

Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
pmid32469301      J+Med+Microbiol 2020 ; 69 (6): 864-873
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • Potential RNA-dependent RNA polymerase inhibitors as prospective therapeutics against SARS-CoV-2 #MMPMID32469301
  • Pokhrel R; Chapagain P; Siltberg-Liberles J
  • J Med Microbiol 2020[Jun]; 69 (6): 864-873 PMID32469301show ga
  • Introduction. The emergence of SARS-CoV-2 has taken humanity off guard. Following an outbreak of SARS-CoV in 2002, and MERS-CoV about 10 years later, SARS-CoV-2 is the third coronavirus in less than 20 years to cross the species barrier and start spreading by human-to-human transmission. It is the most infectious of the three, currently causing the COVID-19 pandemic. No treatment has been approved for COVID-19. We previously proposed targets that can serve as binding sites for antiviral drugs for multiple coronaviruses, and here we set out to find current drugs that can be repurposed as COVID-19 therapeutics.Aim. To identify drugs against COVID-19, we performed an in silico virtual screen with the US Food and Drug Administration (FDA)-approved drugs targeting the RNA-dependent RNA polymerase (RdRP), a critical enzyme for coronavirus replication.Methodology. Initially, no RdRP structure of SARS-CoV-2 was available. We performed basic sequence and structural analysis to determine if RdRP from SARS-CoV was a suitable replacement. We performed molecular dynamics simulations to generate multiple starting conformations that were used for the in silico virtual screen. During this work, a structure of RdRP from SARS-CoV-2 became available and was also included in the in silico virtual screen.Results. The virtual screen identified several drugs predicted to bind in the conserved RNA tunnel of RdRP, where many of the proposed targets were located. Among these candidates, quinupristin is particularly interesting because it is expected to bind across the RNA tunnel, blocking access from both sides and suggesting that it has the potential to arrest viral replication by preventing viral RNA synthesis. Quinupristin is an antibiotic that has been in clinical use for two decades and is known to cause relatively minor side effects.Conclusion. Quinupristin represents a potential anti-SARS-CoV-2 therapeutic. At present, we have no evidence that this drug is effective against SARS-CoV-2 but expect that the biomedical community will expeditiously follow up on our in silico findings.
  • |Animals[MESH]
  • |Antiviral Agents/*pharmacology/therapeutic use[MESH]
  • |Betacoronavirus/*drug effects/enzymology/genetics/physiology[MESH]
  • |COVID-19[MESH]
  • |Coronavirus Infections/*drug therapy/virology[MESH]
  • |Drug Evaluation, Preclinical/methods[MESH]
  • |Drug Synergism[MESH]
  • |Humans[MESH]
  • |Molecular Conformation[MESH]
  • |Pandemics[MESH]
  • |Phylogeny[MESH]
  • |Pneumonia, Viral/*drug therapy/virology[MESH]
  • |RNA-Dependent RNA Polymerase/*antagonists & inhibitors/drug effects[MESH]
  • |Rifampin/pharmacology[MESH]
  • |SARS-CoV-2[MESH]
  • |Sequence Alignment[MESH]
  • |Sequence Analysis, Protein[MESH]
  • |Virginiamycin/analogs & derivatives/pharmacology[MESH]


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    Linkout box